Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model

Na Young Yoon, Min young Jung, Dong Hye Kim, Hae Jin Lee, Eung Ho Choi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Congenitally or early impaired skin barrier as the first event starting the ‘atopic march’ in atopic dermatitis (AD) patients can increase allergen penetration that results in sensitization, even in the airways, followed by asthma and allergic rhinitis. Thymic stromal lymphopoietin (TSLP) is a cytokine existing in high levels in AD skin and is considered as a novel therapeutic target for atopic disease. We generated oxazolone (Ox)-induced AD-like (Ox-AD) hairless mice and divided them into four groups according to the therapeutic challenges: topical glucocorticoid, pimecrolimus, emollient, and control (acetone-only treated). We assessed the functional studies of skin barrier, epidermal expressions of differentiation markers, IL-1α, TNF-α, proteinase-activated receptor-2 (PAR-2), TSLP and antimicrobial peptides (AMP), and serum IgE in each group. Topical glucocorticoid or pimecrolimus treatment improved AD-like skin lesions and barrier functions, and restored the epidermal expression of differentiation markers, IL-1α, TNF-α, PAR-2, and TSLP, in Ox-AD mice. The improvement was relatively better with the glucocorticoid than pimecrolimus. Epidermal AMP expression was restored by topical glucocorticoid, but not pimecrolimus. Our result showed that topical glucocorticoid or pimecrolimus improved the AD-like skin lesions and barrier impairment by suppressing TSLP-related allergic inflammation.

Original languageEnglish
Pages (from-to)569-581
Number of pages13
JournalArchives of Dermatological Research
Volume307
Issue number7
DOIs
Publication statusPublished - 2015 Sep 21

Fingerprint

Oxazolone
Atopic Dermatitis
Glucocorticoids
Skin
PAR-2 Receptor
Differentiation Antigens
Interleukin-1
Therapeutics
Emollients
Hairless Mouse
Peptides
Acetone
Allergens
Immunoglobulin E
pimecrolimus
thymic stromal lymphopoietin
Asthma
Cytokines
Inflammation
Serum

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{b101abf177064ad992b721135d290865,
title = "Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model",
abstract = "Congenitally or early impaired skin barrier as the first event starting the ‘atopic march’ in atopic dermatitis (AD) patients can increase allergen penetration that results in sensitization, even in the airways, followed by asthma and allergic rhinitis. Thymic stromal lymphopoietin (TSLP) is a cytokine existing in high levels in AD skin and is considered as a novel therapeutic target for atopic disease. We generated oxazolone (Ox)-induced AD-like (Ox-AD) hairless mice and divided them into four groups according to the therapeutic challenges: topical glucocorticoid, pimecrolimus, emollient, and control (acetone-only treated). We assessed the functional studies of skin barrier, epidermal expressions of differentiation markers, IL-1α, TNF-α, proteinase-activated receptor-2 (PAR-2), TSLP and antimicrobial peptides (AMP), and serum IgE in each group. Topical glucocorticoid or pimecrolimus treatment improved AD-like skin lesions and barrier functions, and restored the epidermal expression of differentiation markers, IL-1α, TNF-α, PAR-2, and TSLP, in Ox-AD mice. The improvement was relatively better with the glucocorticoid than pimecrolimus. Epidermal AMP expression was restored by topical glucocorticoid, but not pimecrolimus. Our result showed that topical glucocorticoid or pimecrolimus improved the AD-like skin lesions and barrier impairment by suppressing TSLP-related allergic inflammation.",
author = "Yoon, {Na Young} and Jung, {Min young} and Kim, {Dong Hye} and Lee, {Hae Jin} and Choi, {Eung Ho}",
year = "2015",
month = "9",
day = "21",
doi = "10.1007/s00403-015-1558-y",
language = "English",
volume = "307",
pages = "569--581",
journal = "Archives of Dermatological Research",
issn = "0340-3696",
publisher = "Springer Verlag",
number = "7",

}

Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model. / Yoon, Na Young; Jung, Min young; Kim, Dong Hye; Lee, Hae Jin; Choi, Eung Ho.

In: Archives of Dermatological Research, Vol. 307, No. 7, 21.09.2015, p. 569-581.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model

AU - Yoon, Na Young

AU - Jung, Min young

AU - Kim, Dong Hye

AU - Lee, Hae Jin

AU - Choi, Eung Ho

PY - 2015/9/21

Y1 - 2015/9/21

N2 - Congenitally or early impaired skin barrier as the first event starting the ‘atopic march’ in atopic dermatitis (AD) patients can increase allergen penetration that results in sensitization, even in the airways, followed by asthma and allergic rhinitis. Thymic stromal lymphopoietin (TSLP) is a cytokine existing in high levels in AD skin and is considered as a novel therapeutic target for atopic disease. We generated oxazolone (Ox)-induced AD-like (Ox-AD) hairless mice and divided them into four groups according to the therapeutic challenges: topical glucocorticoid, pimecrolimus, emollient, and control (acetone-only treated). We assessed the functional studies of skin barrier, epidermal expressions of differentiation markers, IL-1α, TNF-α, proteinase-activated receptor-2 (PAR-2), TSLP and antimicrobial peptides (AMP), and serum IgE in each group. Topical glucocorticoid or pimecrolimus treatment improved AD-like skin lesions and barrier functions, and restored the epidermal expression of differentiation markers, IL-1α, TNF-α, PAR-2, and TSLP, in Ox-AD mice. The improvement was relatively better with the glucocorticoid than pimecrolimus. Epidermal AMP expression was restored by topical glucocorticoid, but not pimecrolimus. Our result showed that topical glucocorticoid or pimecrolimus improved the AD-like skin lesions and barrier impairment by suppressing TSLP-related allergic inflammation.

AB - Congenitally or early impaired skin barrier as the first event starting the ‘atopic march’ in atopic dermatitis (AD) patients can increase allergen penetration that results in sensitization, even in the airways, followed by asthma and allergic rhinitis. Thymic stromal lymphopoietin (TSLP) is a cytokine existing in high levels in AD skin and is considered as a novel therapeutic target for atopic disease. We generated oxazolone (Ox)-induced AD-like (Ox-AD) hairless mice and divided them into four groups according to the therapeutic challenges: topical glucocorticoid, pimecrolimus, emollient, and control (acetone-only treated). We assessed the functional studies of skin barrier, epidermal expressions of differentiation markers, IL-1α, TNF-α, proteinase-activated receptor-2 (PAR-2), TSLP and antimicrobial peptides (AMP), and serum IgE in each group. Topical glucocorticoid or pimecrolimus treatment improved AD-like skin lesions and barrier functions, and restored the epidermal expression of differentiation markers, IL-1α, TNF-α, PAR-2, and TSLP, in Ox-AD mice. The improvement was relatively better with the glucocorticoid than pimecrolimus. Epidermal AMP expression was restored by topical glucocorticoid, but not pimecrolimus. Our result showed that topical glucocorticoid or pimecrolimus improved the AD-like skin lesions and barrier impairment by suppressing TSLP-related allergic inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84943698971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943698971&partnerID=8YFLogxK

U2 - 10.1007/s00403-015-1558-y

DO - 10.1007/s00403-015-1558-y

M3 - Article

VL - 307

SP - 569

EP - 581

JO - Archives of Dermatological Research

JF - Archives of Dermatological Research

SN - 0340-3696

IS - 7

ER -